Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management
LSP, headquartered in Amsterdam, the Netherlands, is a venture capital firm that invests in innovative companies with strong scientific and clinical rationale across several life sciences strategies. LSP was founded in 1998 and today is one of Europe’s largest and most experienced life sciences investment firms. LSP employs a large number of professionals across its offices in Amsterdam, Munich and Boston. Over the past two decades, LSP has invested in over 150 life sciences companies, generated strong returns, and built a top-performing life sciences franchise. As part of EQT, the LSP team will be able to continue to operate in the same successful manner as they have been operating over the past two decades.
EQT AB will acquire 100 percent of the LSP management companies and 20 percent of the right to carried interest in select LSP funds. In addition, EQT AB will be entitled to 35 percent of the carried interest of future funds. The upfront consideration amounts to EUR 450 million (on a cash- and debt free basis) comprising of 25 percent cash and 75 percent EQT AB publicly traded shares.
Vinge’s team consisted of Christina Kokko, Karl Klackenberg and Milad Kamali (M&A), Sofie Bjärtun (Equity Capital Markets), Emma Johansson and Johan Wahlbom (Competition) and Emma Stuart-Beck and Caroline Krassén (Regulatory) and Ellinor Gyllenhammar (VDR Expert). Vinge has advised EQT together with Debevoise & Plimpton LLP (Investment Funds) and Loyens & Loeff (Dutch law)
